Professor of Pediatrics, Dana-Farber Cancer Institute
Hematology
Dr. Stephen E. Sallan, MD
|
|
Give Review
Stephen E. Sallan, MD practices Hematology. He went to Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine He received 8 awards: "Pediatric Oncology Award", "Boston Red Sox Biomedical All-Star", "Boston Magazine", "America's Top Doctors", "Distinguished Alumni Award", "James Carreras Prize for International Pediatrician of the Year", "America's Top Doctors for Cancer" and "Super Doctor". Stephen Sallan is a published physician. He published 66 publications, including: 'Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.'
Publications
- Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.
- Intravenous pegylated asparaginase versus intramuscular native Escherichia colil-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001):...
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
- An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
- Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
- Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.
- Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.
- Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
- c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
- Therapeutic approaches to haematological malignancies in adolescents and young adults.
- Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
- Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute All Co...
- Functional and structural differences in the hippocampus associated with memory deficits in adult survivors of acute lymphoblastic leukemia.
- Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
- Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.
- Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
- ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.
- The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia.
- Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years po...
- Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer ...
- The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Da...
- Differentiation of NUT midline carcinoma by epigenomic reprogramming.
- Aberrant Expression of Functional BAFF-System Receptors by Malignant B-Cell Precursors Impacts Leukemia Cell Survival.
- Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
- Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.
- Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
- Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
- Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
- DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.
- Treating childhood leukemia without cranial irradiation.
- Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
- High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
- Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
- BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
- Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic le...
- Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells.
- Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
- Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.
- Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.
- Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia.
- Wise up: do not do it without protection!
- Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
- Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
- Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.
- Cardiac changes associated with growth hormone therapy among children treated with anthracyclines.
- Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
- Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
- The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
- Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neuroto...
- FLT3 mutations in childhood acute lymphoblastic leukemia.
- IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.
- Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implicati...
- Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
- Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.
- Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment.
- Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.
- Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis.
- Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
- Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
- Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.
- Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.
- Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
- Cardiovascular disease in adult survivors of childhood cancer.
Schools
Wayne State University
Boston Fltg Hospital
Children39s Hospital Of Philadelphia
Hospital Sick Chldn
Chldns Hospital Med Center Harvard
Doctors Specialties
- Pediatrics
- Hematology
Accepted Insurances
Awards
- Pediatric Oncology Award
- Boston Red Sox Biomedical All-Star
- Boston Magazine
- America's Top Doctors
- Distinguished Alumni Award
- James Carreras Prize for International Pediatrician of the Year
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Boston Children's Hospital -
Children's Hospital of Philadelphia -
Tufts Medical Center -
Wayne State University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Boston Children's Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Rushdia Z. Yusuf, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Gaudet Jr., MD |
|
|
Dr. Kathleen M. Mahoney, MD |
|
|
Dr. Paul E. Goss, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Anna F. Farago, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Gaughan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce Furie, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Yujuan Zhang, BM
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan P. Perrine, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|